Comparison of the Pharmacokinetic and Pharmacodynamic Properties of Biocon's Insulin R U-500 With Humulin® R U-500 (US Reference Product) in Healthy Subjects

Biocon Limited78 enrolled

Overview

Single-centre, randomised, double-blind, three-period, six-sequence, partially replicated design, crossover trial in healthy subjects

The present study is designed to demonstrate pharmacokinetic and pharmacodynamic equivalence of Biocon's Human Insulin R U-500 with Humulin® R U-500 in healthy subjects. The treatment consists of one single dose of the test or reference product, administered during each of the three study periods, separated by 5-7 days between each dosing. The planned trial duration for each subject is about 18 to 44 days. Eligible subjects will undergo three euglycaemic clamp examinations (each of 24 hours duration). Depending on the sequence in which a particular subject is randomized, each subject will either undergo two clamps with administration of test product plus one clamp with administration of reference product, or, two clamps with administration of reference product plus one clamp with administration of test product, in random order.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

DOUBLE

Enrollment

Conditions

Healthy Volunteers

Interventions

Biocon's Human Insulin R U-500BIOLOGICAL

Biocon's Human Insulin R U-500 (Insulin Human Injection 500 units/mL), 3 mL cartridges (containing 1,500 units of insulin).

Humulin® R U-500 (US Reference Product)BIOLOGICAL

Humulin® R U-500 (US Reference Product), 3 mL single-patient-use KwikPen® (containing 1,500 units of insulin)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy male or post-menopausal female subjects. The post-menopausal state is defined as no menses for 12 months without an alternative medical cause and confirmed by a follicle stimulating hormone (FSH) level in the post-menopausal range (≥ 25.8 IU/L). * Age between 18 and 55 years, both inclusive. * Body Mass Index (BMI) between 18.5 and 29.0 kg/m2, both inclusive. * Fasting plasma glucose concentration ≤ 100 mg/dL. * Considered generally healthy upon completing the medical history and screening safety assessments, as judged by the Investigator. Exclusion Criteria: * Known or suspected hypersensitivity to investigational medicinal products (IMPs) or related products. * Receipt of any medicinal product in clinical development within 30 days or five times its half-life (whichever is longer) before randomisation in this trial. * Systolic blood pressure \< 90 mmHg or \> 139 mmHg and/or diastolic blood pressure \< 50 mmHg or \> 89 mmHg after resting for at least 5 minutes in the supine position (excluding white-coat hypertension; therefore, a repeat test showing results within range will be acceptable). * Pulse rate at rest outside the range of 50-90 beats per minute.

Locations (1)

Profil Institut für Stoffwechselforschung GmbH 9

Neuss, Germany

Outcomes

Primary Outcomes

Primary pharmacokinetics (PK) endpoint: area under the insulin concentration curve(AUCins).0-12h

Area under the insulin concentration curve

Time frame: 0 to12 hours

Primary pharmacokinetics (PK) endpoint: maximum observed insulin concentration(Cins.max)

Maximum observed insulin concentration

Time frame: NAP (Not Applicable)

Primary pharmacodynamics (PD) endpoint:area under the glucose infusion rate curve (AUCGIR)0-12h

Area under the glucose infusion rate curve

Time frame: 0 to 12 hours

Primary pharmacodynamics (PD) endpoint:maximum observed glucose infusion rate (GIRmax)

Maximum observed glucose infusion rate

Time frame: NAP (Not Applicable)

Secondary Outcomes

Secondary pharmacokinetics (PK) endpoint: area under the insulin concentration-time curve(AUCins).0-infinity

Area under the insulin concentration-time curve

Time frame: 0 hours to 24 hours

Secondary pharmacokinetics (PK) endpoint: area under the insulin concentration-time curve(AUCins).0-24h

Area under the insulin concentration-time curve

Time frame: 0 to 24 hours

Secondary pharmacokinetics (PK) endpoint: area under the insulin concentration-time curve (AUCins).12-24h

Area under the insulin concentration-time curve

Time frame: 12 to 24 hours

Secondary pharmacokinetics (PK) endpoint:time to maximum observed insulin concentration (tmax.ins)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.